WONG, Kam Wai,LAW, Yuen Kwan,EFFERTH, Thomas,KADIOGLU, Onat,LIU, Liang
申请号：
AU2015101721
公开号：
AU2015101721A4
申请日:
2015.11.26
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
#$%^&*AU2015101721A420160107.pdf#####ABSTRACT The present invention relates to the administration of a prenylated isoflavone and its effects on subjects with multidrug-resistant cancer, in particular a multidrug-resistant cancer with enhanced expression or functional activity of ABC transporter proteins such as P-glycoprotein, i.e. a specific subgroup of subjects with cancer. It has been found that the prenylated isoflavone is suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in said cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant. Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit comprising a prenylated isoflavone and a chemotherapeutic compound is provided. 43WORK, Fig 1'A~ 3 0 (.-.ily 3 Fi .
